Previous 10 | Next 10 |
2023-09-19 06:36:29 ET Summary RANI is developing a payload agnostic robotic pill (RaniPill) with enormous potential for penetration of several multi-billion injectable drug delivery markets. Pre-clinical and early-phase human studies consistently show effective and safe oral deli...
- Topline results from this study are expected in early Q1 2024 - Celltrion has a right of first negotiation for RT-111 following positive Phase 1 results SAN JOSE, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or ...
- Two preclinical studies of RaniPill ® HC achieved 18/20 successful drug delivery of orally administered teriparatide resulting in a cumulative 90% success rate - Rani will continue preclinical testing to confirm preliminary reliability rate and optimize device performan...
SAN JOSE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that Rani will participat...
2023-08-11 16:23:30 ET Rani Therapeutics press release ( NASDAQ: RANI ): Q2 GAAP EPS of -$0.37 beats by $0.04 . Cash, cash equivalents and marketable securities as of June 30, 2023, totaled $74.6 million. For further details see: Rani Therapeutics GAAP EPS of...
- Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three abstracts on RT-102 and RT-112 at the Endocrine Society Annual Conference and select...
SAN JOSE, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will part...
SAN JOSE, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced that its abstract entitled ...
SAN JOSE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that a late-breaking abstr...
SAN JOSE, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has expanded its p...
News, Short Squeeze, Breakout and More Instantly...
Rani Therapeutics Holdings Inc. Company Name:
RANI Stock Symbol:
NASDAQ Market:
Rani Therapeutics Holdings Inc. Website:
~ New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~ ~ Rani and Pr...
2024-05-16 19:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will parti...